The trial enlisted 51 adults facing complete oesophageal food bolus impaction, excluding those who ingested bone-containing meat and individuals with higher ASA physical status classifications. The intervention group (28 patients) was instructed to consume 25 mL cups of cola at intervals, up to a maximum total volume of 200 mL. In contrast, the control group (23 patients) awaited spontaneous passage. If symptoms persisted, endoscopic removal followed current guidelines. Primary outcomes focused on the improvement of food bolus obstruction and complete passage, with adverse events related to the intervention also considered.
Enhancement in oesophageal food bolus obstruction, reported by patients (comprising both complete and partial passage), and assessment specifically focusing on complete passage constituted the primary outcome. The secondary outcome involved any adverse events related to interventions.
Findings:
- Contrary to expectations, the study revealed that cola consumption did not significantly enhance the rate of improvement in complete oesophageal food bolus impaction.
- Both the intervention and control groups demonstrated a 61% rate of improvement in food bolus obstruction.
- Although the intervention group reported a higher incidence of complete passage (43% vs. 35%), the difference lacked statistical significance. Importantly, no severe adverse events occurred, affirming the safety of the cola treatment.
- However, 21% of patients in the intervention group experienced temporary discomfort after consuming cola.
The study's findings imply that while cola may offer some relief, it may not serve as a definitive solution for complete oesophageal food bolus impaction. Researchers caution against relying solely on cola, emphasizing the need for prompt endoscopic intervention when necessary. The study suggests that cola could be considered as a first-line treatment, but its use should not impede the timely planning of endoscopic management.
Further reading: Efficacy of cola ingestion for oesophageal food bolus impaction: open label, multicentre, randomised controlled trial. doi: https://doi.org/10.1136/bmj-2023-077294
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.